Piperno-Neumann S, Carlino MS, Boni V, et al. A phase I trial of LXS196, a PKC inhibitor for uveal melanoma. SMR 2017, abstract SMR09-1.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker